## **Product Information and Testing**

## **Product Information**

Product Name	Zeng01i-iPSH9			
Alias	WA09			
Lot Number	DB0014			
Depositor	Buck Institute for Resarch on Aging			
Banked by	WiCell			
Thaw Recommendation	Thaw 1 vial into 2 wells of a 6 well plate. WiCell recommends thawing using ROCK Inhibitor for best results.			
Culture Platform	Feeder Dependent			
	Medium: hES Medium			
	Matrix: MEF			
Protocol	WiCell Feeder Dependent Protocol			
Passage Number	p20			
	These cells were cultured for 19 passages prior to freeze. The Depositor adds +1 to the passage number at freeze so that the number on the vial best represents the overall passage number of the cells at thaw.			
Date Vialed	05-February-2014			
Vial Label	H9 IPS clone2			
	p20 02/05/2014			
Discofety and Use Information	AIVIS IVIEF			
Biosalety and Use information Appropriate biosalety precations should be followed when working with these cells. The end user is a pandiad and stored in an appropriate mapper. WiCell is n				
	responsible for damages or injuries that may result from the use of these cells.			
	Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.			

## Testing Performed by WiCell

Test Description	Test Provider	Test Method	Test Specification	Result
Post-Thaw Viable Cell Recovery	WiCell	SOP-CH-305	Recoverable attachment after	Pass
			passage	
Identity by STR	UW Translational Research Initiatives in Pathology	PowerPlex 16 HS System by Promega	Consistent with known profile	Pass
Sterility	Biotest Laboratories	ST/07	Negative	Pass
Mycoplasma	WiCell	SOP-QU-004	Negative	Pass
Karyotype by G-banding	WiCell	SOP-CH-003	Report karyotype	Pass

Date of Lot Release	Quality Assurance Approval
	4/27/2015
20-April-2014	Хамк
	AMK Quality Assurance Signed by:

©2015 WiCell Research Institute

The material provided under this certificate has been subjected to the tests specified and the results and data described herein are accurate based on WiCell's reasonable knowledge and belief. Appropriate Biosafety Level practices and universal precautions should always be used with this material. For clarity, the foregoing is governed solely by WiCell's Terms and Conditions of Service, which can be found at http://www.wicell.org/privacyandterms.

# **Short Tandem Repeat Analysis\***



Department of Pathology and Laboratory Medicine TRIP Laboratory (Molecular) http://www.pathology.wisc.edu/research/trip

#### **Samples Report:**

11092-STR 201.3 ng/μL (A260/280=1.92) Sample Name on Tube: 11092-STR DNA Extracted by: TRIP Lab



600 Highland Avenue, K4/459 Madison, WI 53792-8550 (608) 262-5173

> Sample Date: 12-30-14 Receive Date: 1-5-15 Assay Date: 1-6-15 File Name: STR\_150109\_JAM and WMR Report Date: 1-12-15

STR Locus	STR Genotype Repeat #	11092-STR
FGA	Identifying information has been redacted to protect donor confidentiality. If more information is required please, contact WiCell's Technical Support	26,28
TPOX		10,11
D8S1179		8,14
vWA		17,17
Amelogenin		X,X
Penta_D		9,13
CSF1PO		11,11
D16S539		12,13
D7S820		9,11
D13S317		9,9
D5S818		11,12
Penta_E		11,14
D18S51		13,13
D21S11		30,30
TH01		9.3,9.3
D3S1358		13.16

Comments: Based on the 11092-STR cells submitted by WiCell QA dated and received on 1-5-15, this sample (Label on Tube: 11092-STR) exactly matches the STR profile of the human stem cell line WA09 comprising 24 allelic polymorphisms across the 15 STR loci analyzed. No STR polymorphisms other than those corresponding to the human WA09 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. This result suggests that the 11092-STR sample submitted corresponds to the WA09 stem cell line and was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~2-5%.

Date TRIP Laboratory, Molecular



Molecular Diagnostics Laboratory

Remember to acknowledge TRIP in your publications, posters & presentations. For details, visit: http://www.pathology.wisc.edu/research/trip/acknowledging

\* Testing was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.

	Steri	lity	Report
--	-------	------	--------

Making life-saving products possible

WiCell Research Institute, I	Inc.	BIOTEST SAMPLE #	14041244				
WICEII QUAIITY Assurance		VALIDATION #	NG				
		TEST PURPOSE	NG				
PRODUCT	WA07-WB0289 #10959, WA07-WB0 iPS-GM01715-DB0030 #10962, iPS-0 iPS-GM12365-DB0032 #10964, iPS-0 iPSH14-DB0013 #10966, H9iPSclone	0284 #10960, WA07-WB0 GM07125-DB0031 #1096 GM20920-DB0033 #1096 e2-DB0014 #10967	0291 #10961, 63, 65,				
PRODUCT LOT	NA						
STERILE LOT	NA	BI LOT	NA				
STERILIZATION LOT	NA	BI EXPIRATION DATE NA					
STERILIZATION DATE	NA	DATE RECEIVED	2014-04-22				
STERILIZATION METHOD	NA	TEST INITIATED	2014-04-23				
SAMPLING BLDG / ROOM	NA	TEST COMPLETED	TEST COMPLETED 2014-05-08				
REFERENCE	Processed according to LAB-003:	Sterility Test Procedure					
	Nine (9) products were each divid were then cultured at 20-25 C and minimum of 14 days.	ded between 40 mL TSB d 30-35 C respectively c	and 40 mL FTG. The samples and were monitored for a				
	USP BI Manufacturers Specifications Other						
RESULTS Non-Sterile	# POSITIVES # TESTED 2 9	POSITIVE CONTE NA	ROL NEGATIVE CONTROL 2 Negatives				
COMMENTS Nine (9) samples were received at Biotest Laboratories, Inc. Sample WA07-WB0284 was positive in both TSB and FTG. Sample iPS-GM07125 was positive in FTG.							
REVIEWED BY		DATE	15MAY14				

Specific test results may not be indicative of the characteristics of any other samples from the same lot or similar lots. Liability is limited to the costs of the tests

Form: M-002 rev. 11 Effective: 13JUN13 

### Mycoplasma Detection Assay Report Testing Performed by WiCell

Testing Performed by WiCell Quarantine/Sentinel Cultures 12-18-2014 FORM SOP-QU-004.01 Version C Edition 01 Reported by: SS Reviewed by: JB Berthold Monolight 539

		Read	ling A	Α	Read	ling B		Ratio		
#	Sample Name	RLU1	RLU2	Ave	RLU1	RLU2	<b>B</b> Ave	B/A	Result	<b>Comments/Suggestions</b>
1	Zeng0li-iPSH9-DB0014 11092	257	261	259	88	88	88	0.34	Negative	
2	WC009i-FX08-01-DB16398 11095	496	494	495	162	166	164	0.33	Negative	
3	Zeng02i-iPSH14-DB0013 11093	215	212	213.5	84	80	82	0.38	Negative	
4	WA01-WB0113-T15456 Sentinel 132	160	158	159	54	55	54.5	0.34	Negative	
5	WA01-WB0113-T15456 Sentinel 134	165	166	165.5	54	54	54	0.33	Negative	
6	Positive (+) Control	341	348	344.5	6775	6692	6733.5	19.55	Positive	
7	Negative (-) Control	475	475	475	41	37	39	0.08	Negative	





Date Reported: Tuesday, December 30, 2014 Cell Line: Zeng01i-iPSH9-DB0014 Passage#: 21 Date of Sample: 12/22/2014 Specimen: iPSC Results: 46,XX Cell Line Gender: Female Reason for Testing: lot release testing

Investigator: Dan Felkner, CDM



Cell: 4 Slide: 3 Slide Type: Karyotype

Total Counted: 20 Total Analyzed: 8 Total Karyotyped: 4 Band Resolution: 450 - 550

### Interpretation:

This is a normal karyotype. No clonal abnormalities were detected at the stated band level of resolution.

Completed by: , CG(ASCP) Reviewed and Interpreted by: , PhD, FACMG

A signed copy of this report is available upon request.

Date:	Sent By:	Sent To:	QC Review By:
	•••••• <b></b>	••••••	

Limitations: This assay allows for microscopic visualization of numerical and structural chromosome abnormalities. The size of structural abnormality that can be detected is >3-10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is defined as the number of G-bands per haploid genome. It is documented here as "band level", i.e., the range of bands determined from the four karyograms in this assay. Detection of heterogeneity of clonal cell populations in this specimen (i.e., mosaicism) is limited by the number of metaphase cells examined, documented here as "# of cells counted".

This assay was conducted solely for listed investigator/institution. The results may not be relied upon by any other party without the prior written consent of the Director of the WiCell Cytogenetics Laboratory. The results of this assay are for research use only. If the results of this assay are to be used for any other purpose, contact the Director of the WiCell Cytogenetics Laboratory.

Unless otherwise mutually agreed in writing, the services provided to you hereunder by WiCell Research Institute, Inc. ("WiCell") are governed solely by WiCell's Terms and Conditions of Service, found at www.wicell.org/privacyandterms. Any terms you may attach to a purchase order or other document that are inconsistent, add to, or conflict with WiCell's Terms and Conditions of Service are null and void and of no legal force or effect.